Literature DB >> 34757482

Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery.

Junya Oguma1, Koshiro Ishiyama1, Daisuke Kurita1, Kyohei Kanematsu1, Yusuke Fujii1, Kentaro Kubo1, Shun Yamamoto2, Yoshitaka Honma2, Ken Kato2, Hiroyuki Daiko3.   

Abstract

BACKGROUND: The aim of the present study was to clarify an appropriate staging system for patients with locally advanced esophageal squamous cell carcinoma (LAESCC) after neoadjuvant chemotherapy (NAC) prior to surgery.
METHODS: A total of 388 patients with clinical stage II or III LAESCC who had undergone NAC followed by an esophagectomy with three-field lymphadenectomy were retrospectively reviewed.
RESULTS: The relapse-free survival (RFS) curves plotted using ypN grading and ypTNM staging both monotonically decreased as the classification number increased, and the groups were more clearly separated than when the Japanese Classification (JC) was applied. A multivariate analysis of relapse free survival (RFS) suggested that ypN (HR = 2.911, P < 0.001), lymphovascular invasion (LVI) (HR = 2.608, P < 0.001) were independent factors associated with OS. The LVI+/ypN+ group had a significantly poorer outcome than the other groups (P < 0.001). The 5-year RFS rates for patients with ypStage IIIA or higher among the LVI-negative cases and ypStage II or higher among the LVI-positive cases were around 0.6 or under. The novel pathological staging which was based on the present results was proposed and RFS curves of each novel stage suggested the suitability of these staging for our cohort.
CONCLUSIONS: The present results suggest that a novel pathological staging system using the ypTNM classification, in which the supraclavicular lymph node was regarded as a regional lymph node and the presence of LVI was included as a category, was appropriate for patients with LAESCC after NAC prior to surgery.
© 2021. The Author(s) under exclusive licence to The Japan Esophageal Society.

Entities:  

Keywords:  Esophageal cancer; Lymphovascular invasion; Neoadjuvant chemotherapy; Pathological staging; Prognostic factors

Mesh:

Year:  2021        PMID: 34757482     DOI: 10.1007/s10388-021-00891-5

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  2 in total

1.  Prognostic impact of lymphovascular invasion in lymph node-negative superficial esophageal squamous cell carcinoma.

Authors:  J Oguma; S Ozawa; A Kazuno; M Yamamoto; Y Ninomiya; K Yatabe; H Makuuchi; G Ogura
Journal:  Dis Esophagus       Date:  2019-12-30       Impact factor: 3.429

2.  The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Masashi Takeuchi; Hirofumi Kawakubo; Shuhei Mayanagi; Kayo Yoshida; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

  2 in total
  1 in total

1.  The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy.

Authors:  Masahiro Adachi; Naoki Aoyama; Motohiro Kojima; Naoya Sakamoto; Saori Miyazaki; Tetsuro Taki; Reiko Watanabe; Kazuto Matsuura; Daisuke Kotani; Takashi Kojima; Takeo Fujita; Keiji Tabuchi; Genichiro Ishii; Shingo Sakashita
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-06       Impact factor: 4.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.